Recently, a fusion protein of an NOD-like receptor family member X1 (NLRX1) and blood–brain barrier-permeable peptide dNP2 treated experimental autoimmune encephalomyelitis in mice [134] and a peptide that selectively recognizes the CNS was used for targeted drug delivery to the CNS in mice [135]. Here, NLRX1 is linked to experimental autoimmune encephalomyelitis.